The trend of developing new disease-modifying drugs in Alzheimer's disease

Hiroyuki Arai, Katsutoshi Furukawa, Naoki Tomita, Aiko Ishiki, Nobuyuki Okamura, Yukitsuka Kudo

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Development of symptomatic treatment of Alzheimer s disease by cholinesterase inhibitors like donepezil was successful. However, it is a disappointment that development of disease-modifying drugs such as anti-amyloid drug based on amyloid-cascade theory has been interrupted or unsuccessful. Therefore, we have to be more cautious regarding inclusion criteria for clinical trials of new drugs. We agree that potentially curative drugs should be started before symptoms begin as a preemptive therapy or prevention trial. The concept of personalized medicine also is important when ApoE4-related amyloid reducing therapy is considered. Unfortunately, Japanese-ADNI has suffered a setback since 2014. However, Ministry of Health, Labour and Welfare gave a final remark that there was nothing wrong in the data managing process in the J-ADNI data center. We should pay more attention to worldwide challenges of speeding up new drug development.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number3
Publication statusPublished - 2016 Mar 1


Dive into the research topics of 'The trend of developing new disease-modifying drugs in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this